SCHEMBL5451710

SCHEMBL5451710

CCNCC(=O)Nc1sc2c(c1C(N)=O)CCOC2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.58
KDM4E B2RXH2 2/20 0.53
FLT3 P36888 1/20 0.53
MAPK1 P28482 1/20 0.53
ALDH1A1 P00352 5/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
ALOX15 P16050 1/20 0.51
HSD17B10 Q99714 1/20 0.51
ANO1 Q5XXA6 1/20 0.51
PTPRC P08575 1/20 0.50
PTPN2 P17706 1/20 0.50
PTPN1 P18031 1/20 0.50
PTPRB P23467 1/20 0.50
PTPRE P23469 1/20 0.50
CNR2 P34972 5/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
MEN1 O00255 1/20 0.49
RAB9A P51151 1/20 0.49
MAPK10 P53779 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459999 0.89 CFTR (0.54) CFTRKDM4EFLT3MAPK1ALDH1A1
SCHEMBL5463020 0.87 CFTR (0.55) CFTRKDM4EFLT3MAPK1ALDH1A1
SCHEMBL5460509 0.86 CFTR (0.53) CFTRKDM4EFLT3MAPK1ALDH1A1
SCHEMBL5458688 0.85 SMN1; SMN2 (0.61) CFTRKDM4EFLT3MAPK1ALDH1A1
SCHEMBL5467640 0.83 CFTR (0.58) CFTRKDM4EFLT3MAPK1ALDH1A1
SCHEMBL5460139 0.83 CFTR (0.60) CFTRKDM4EFLT3MAPK1ALDH1A1
SCHEMBL5445049 0.83 CFTR (0.60) CFTRKDM4EFLT3MAPK1ALDH1A1
SCHEMBL5451681 0.83 CFTR (0.54) CFTRKDM4EFLT3MAPK1ALDH1A1
SCHEMBL5455157 0.82 CNR2 (0.69) CFTRKDM4EFLT3MAPK1ALDH1A1
SCHEMBL5467138 0.82 CFTR (0.62) CFTRKDM4EFLT3MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885KDM4E 3417/4885FLT3 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.